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Many human tumors have elevated DT-diaphorase activities, such
as liver (Beyer et al, 1987), colon (Schlager et al, 1990), lung
(Malkinson et al, 1992) and breast (Berger et al, 1985). In the case
of lung tumours, elevated NQO1 activity has recently been
reported in non-small cell lung cancer (NSCLC) cell lines and
primary tumours relative to SCLC and uninvolved lung (Schlager
and Powis, 1990; Malkinson et al, 1992; Smitskamp-Wilms et al,
1995). This work validated NSCLC as a potential target against
which anti-tumour drugs, which are efficiently bioactivated by
NQO1, can be tested for their cytotoxicity. Biochemical studies
have already demonstrated that NQO1 activity is induced by a
wide range of chemicals including polycyclic aromatic hydro-
carbons, azo dyes and phenolic antioxidants (Benson et al, 1980;
DeLong et al, 1986; Joseph et al, 1994; Talalay and Prochaska,
1987; Talalay et al, 1988). Sequence analysis of the 5¢ flanking
region of the human NQO1 gene shows the presence of an acti-
vator protein 2 (AP-2), antioxidant response element (ARE), also
called the electrophile response element (EpRE), a xenobiotic
response element (XRE) and a nuclear factor kB (NFkB)-like
element within 900 bp of the transcriptional start site (Jaiswal,
1991). Interestingly, the ARE in the human NQO1 gene (–477 to
–438) actually contains a centrally-located perfect AP-1 site,
flanked by two imperfect AP-1 elements. In this study, we exam-
ined the mechanisms underlying the differential basal expression
of hNQO1 in NSCLC versus SCLC. Initially, Jaiswal et al charac-
terized the ARE in the hNQO1 gene in a hepatoma cell line and
suggested that multiple AP-1 proteins bind to this DNA sequence
(Li and Jaiswal, 1992, 1994). In this report, we have performed
functional assays to identify the cis DNA elements important in
the transcriptional regulation of NQO1 in human lung tumour
cells. Our data indicate that the ARE is important in regulating
NQO1 promoter activity in NSCLC. We have also examined
binding activity of Fos and Jun protein family members to the
hNQO1 ARE and demonstrate Fra1, Fra2 and JunB binding
activity only in NSCLC cell lines that constituitively express
NQO1.
MATERIALS AND METHODS
Cell lines and cell culture
The human NSCLC cell lines (NCI-H460, NCI-H520, A549) were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA) and were maintained in modified Eagles
medium (MEM) supplemented with 2 mM L-glutamine, 100 units
ml–1 penicillin, 100 mg ml–1 streptomycin and 10% fetal bovine
serum (Summit Biotechnology, Fort Collins, CO, USA). The
human SCLC cell lines (NCI-H146, NCI-H82, NCI-H187) were
also obtained from ATCC and were maintained in RPMI-
1640 with the same supplements. PCR-RFLP (polymerase chain
reaction-restriction fragment length polymorphism) (Traver et al,
1997) was performed on these six cell lines to ensure wild-type or
heterozygous NQO1 polymorphism status (wild-type: H460,
A549, H146, H82; heterozygous: H520, H187).
Construction of plasmids
The reporter plasmid vector, pGL3 (Promega, Madison, WI,
USA) contains a synthetic polyadenosine (poly-A) signal placed
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Correspondence to: D Rossupstream of the firefly luciferase gene and a SV40 late poly-A
signal downsteam of the reporter gene. A 1765 bp fragment
(–1539 to + 115) of the hNQO1 gene was isolated from a human
placental cosmid library (gift from Dr NW Gibson). To generate 5¢
deletion constructs, convenient restriction enzyme sites were used
to subclone the DNA fragments into the Sma I/Nco I site in pGL3.
Transient DNA transfections
Lipofection of plasmid DNA into the various human lung cells
was performed as described (BRL, Gaithersburg, MD, USA).
Briefly, each 35 mm plate received 1 ´ 106 cells, 1 mg of test
plasmid, 1 ug of pCMVbgal (Clontech, Palo Alto, CA, USA) and
3 ml or 4 ml (NSCLC or SCLC respectively) of Lipofectamine
(BRL, Gaithersburg, MD, USA). Cells were harvested after 24 h,
lysed, and cell debris sedimented. For normalization of transfec-
tion efficiency, cells were transfected in parallel with the control
plasmid, pSV40GL3 (Promega, Madison, WI, USA). Cell extracts
were then assayed for luciferase and b-galactosidase activities
(Promega, Madison, WI, USA).
Nuclear extracts
High salt nuclear extracts were prepared using a modification of
the method of Dignam et al (1983). Briefly, washed pelleted cells
(5–10 ´ 108) were suspended in two packed volumes of 10 mM
Hepes, pH 7.9, 1.5 mM magnesium chloride, 60 mM potassium
chloride and 0.5 mM DTT, and lysed by 15 strokes of an all glass
Dounce homogenizer (B type pestle). The homogenate was
centrifuged to pellet the nuclei. The crude nuclei were resuspended
in 0.6 ml of 20 mM Hepes, pH 7.9, 25% glycerol, 500 mM potas-
sium chloride, 0.5 mM DTT, 1.5 mM magnesium chloride, 0.2 mM
EDTA, pH 8.0 and 0.1 mM EGTA, pH 8.0 and gently shaken for
30 min. After centrifugation, the supernatant was dialysed for 3 h
and then frozen in aliquots at –70°C. The protein concentration in
the nuclear extracts were determined using the Bradford protein
assay (Bio Rad, Richmond, CA, USA).
Electrophoretic gel mobility shift assays
The double stranded oligomer used in the gel shift studies was
synthesized as a complementary pair on an automated DNA
synthesizer. The oligomer was end-labelled using T4 polynucleo-
tide kinase (BRL) and [32]g-ATP (NEN, 3000 Ci mmol–1) to a
specific activity of 10–30 000 cpm and applied to a G-10 Sephadex
column (Clontech, Palo Alto, CA, USA). The human NQO1
promoter fragments were the sense strand, 5¢-AAATCGCAGT-
CACAGTGACTCAGCAGAATCTGAGCCTAGG-3¢ annealed to
the antisense strand, 5-¢CCTAGGCTCAGATTCTGCTGAGT-
CACTGTGACTGCGATTT-3¢ and represented sequences from
–477 to – 438 and contained the ARE; the sense strand, 5¢-
GATTACAGGCGTGAGCACCG-3¢ annealed to the antisense
strand 5¢-CGGTGCTCACGCCTGTAATC-3¢ and represented
sequences from –749 to –730 and contained the XRE; the
sense strand, 5¢-AACAAATTCGTCTCCACGGAGCATGTCT-3¢
annealed to the antisense strand 5¢-AGACATGCTCCGTGGA-
GACGAATTTGTT-3¢ and represented mid-promoter sequences
(MPR) from –527 to –499. The sense strand, 5¢-tcgaGGTA-
ATTTGCATTTCTAA-3¢ was annealed to the antisense strand 5¢-
tcgaTTAGAAATGCAAATTACC-3¢ and represented sequences
–537 to –554 plus TCGA overhangs and contained the octamer
(Oct-1) motif region of the mouse immunoglobin enhancer
(Ephrussi et al, 1985). The sense strand, 5¢-tcgaCTAGT-
GATGAGTCAGCCGGATC-3¢ was annealed to the antisense
strand 5¢-tcgaGATCCGGCTGACTCATCACTAG-3¢ and repre-
sented an artificial consensus AP-1 motif region (Shy et al, 1996)
plus TCGA overhangs. Briefly, 3 mg of nuclear extract were incu-
bated at 25°C for 30 min in binding buffer consisting of 20 mM
Hepes, pH 7.9, 2.5 mM magnesium chloride, 1 mM DTT,
2 mg bovine serum albumin and 10% glycerol with 150 ng poly
dIdC. Approximately 20 000 cpm of end-labelled DNA probe was
added to the reaction and binding carried out at 25°C for an addi-
tional 30 min. The specific polyclonal antibodies were added to
some of the samples after the addition of labelled DNA fragments
and incubated for an additional 30 min at 25°C. Unlabelled frag-
ments were added to some of the samples and pre-incubated for
30 min at 25°C prior to the addition of labelled fragments. Samples
(20 ml) were subjected to electrophoresis on a 5% non-denaturing
polyacrylamide gel (0.25´ TBE) at 25°C and 20 mA for 1 h. Gels
were dried and exposed to Hyperfilm (Amersham, Arlington
Heights, IL, USA) at –70°C.
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Table 1 DT-diaphorase activity in cell lines from lung tumours
Human lung DT-diaphorase activity
cell lines (nmoles min–1 mg–1 protein)
NSCLC/NCI-H460 1782 ± 72
NSCLC/A549 2484 ± 52
NSCLC/NCI-H520 1122 ± 56
SCLC/NCI-H146 6 ± 0.6
SCLC/NCI-H82 3 ± 1.4
SCLC/NCI-H187 3 ± 1.0
Enzyme activities (mean ± s.d.) were determined as described (Malkinson et
al, 1992).
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Figure 1 Human NQO1 promoter constructs. The 5¢ deletion constructs
were prepared using convenient restriction enzyme sites to examine areas
important for basal promoter activity. The 3¢ extent of all inserts was to the
Nco I site at + 115. DNA fragments were inserted into the Sma I-Nco I site in
pGL3RESULTS
DT-diaphorase activity in cell lines derived from human
lung tumours
The six representative cell lines listed in Table 1 have well charac-
terized morphological and growth characteristics. The NSCLC cell
lines were derived from large cell (H460) squamous (H520) and
adenocarcinoma (A549) histological types and each had markedly
elevated DT-diaphorase activity relative to the SCLC cells (H146,
H82 and H187). There was also a good correlation between DT-
diaphorase activity and hNQO1 mRNA content (Malkinson et al,
1992).
NSCLC exhibit greater hNQO1 promoter activity than
SCLC
To identify and characterize potential regulatory regions within the
hNQO1 promoter region, we constructed a series of hNQO1
promoter–LUC constructs with progressive deletions of the prox-
imal and distal hNQO1 promoter starting from nucleotide –1539
(Figure 1). These constructs were transfected using lipofection
into both NSCLC (see Figure 2A for H460 results) and SCLC (see
Figure 2B using H146) cell lines and lysates were assayed for
luciferase expression. The results of multiple experiments,
summarized in Figure 2C, demonstrate different patterns of
promoter activity between NSCLC and SCLC cell lines.
The largest hNQO1 construct (1539/+115) exhibits robust
luciferase expression in the H460, A549, and H520 cell lines
(Figure 2C). Deletion from –1539 to –864 resulted in no signifi-
cant change in luciferase activity and truncation to –608, removing
the NFkB and XRE elements (see Figure 1), maintained this robust
activity (Figure 2C). Further deletion to –259 decreased luciferase
activity by 85–90%, to a range between fivefold (H460, H520) and
23-fold (H549) over the promoterless vector. Interestingly, this
region between –608 and –259 contains the cis element, ARE,
within which lies a perfect AP-1 flanked by two AP-1-like motifs.
In contrast, in the H146, H82 and H187 cell lines, the hNQO1
promoter is much less transcriptionally active (Figure 2B, C). The
data showed that deletion of the region containing the AP-1 site
did not substantially affect the level of luciferase expression.
AP-1 is a component of ARE element-binding activity in
lung cancer cells
To identify which proteins are bound to the ARE element, a gel
shift mobility assay was employed to detect ARE-binding activity
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Figure 2 Basal hNQO1 promoter activity in three NSCLC and three SCLC cell lines. (A, B) Deletion constructs were prepared using convenient restriction
sites. One mg of test plasmid and 1 mg of pCMVbgal were transfected into H460 cells (A) or H146 cells (B) using lipofection. After harvesting 16–18 h after
transfection, lysates were assayed for luciferase and b-galactosidase activity. Data are expressed relative to 106 light units of pSV40GL3 transfected in parallel.
N refers to the number of experiments performed with each construct. (C) The luciferase activity for each plasmid construct is determined relative to that of the
promoterless vector, pGL3. hNQO1 exon 1 is shown as a stippled box; values are shown plus or minus s.e.m.; ® indicates the transcription start site;
t t indicates the position of the ARE (antioxidant response element); (n) indicates the number of experiments performed with each construct
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Relative luciferase activityin nuclear extracts prepared from both NSCLC and SCLC with a
32P-labelled synthetic oligonucleotide spanning –477 to –438 of
the hNQO1 promoter. In nuclear extracts prepared from two
representative cell lines, H460 and H146, we detected specific
ARE-binding activity. This binding activity was abolished by
the presence of a 50-fold excess of either unlabelled ARE or
unlabelled AP-1 consensus oligomer, suggesting that the same
binding proteins are likely to interact with both ARE and AP-1
elements. In contrast, the unlabelled oligomers XRE, MPR, and
Oct-1 were unable to compete any of the specific complexes
(Figure 3). Nuclear extracts prepared from the remaining four cell
lines gave similar results (data not shown).
Differential binding of AP-1 proteins to the hNQO1 ARE
fragment
To characterize further the protein complex binding to the AP-1-
binding site within the ARE region of the hNQO1 gene, nuclear
extracts from NSCLC or SCLC were incubated with antibodies
against panFos, cFos, FosB, Fra1, Fra2 (Figure 4, top panel), and
cJun, JunB, JunD (Figure 4, bottom panel) prior to detection of
1682 JK Kepa and D Ross
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Figure 3 Gel mobility shift assay with cold competitor oligomers. 32P-ARE
oligomer was incubated with nuclear extracts from either H460 NSCLC (top
panel) or H146 SCLC (bottom panel) in the presence of either 0 or 50-fold
molar excess of cold ARE, AP-1, XRE, MPR or Oct-1. The incubations were
then electrophoresed on nondenaturing gels. The arrow indicates the area of
major binding activity
Figure 4 Gel mobility shift assay with various specific AP-1 antibodies. 32P-
ARE oligomer was incubated with nuclear extracts from either H460 NSCLC
(left panel) or H146 SCLC (right panel) followed by the addition of specific
antibodies as indicated. The positions of the DNA–protein shifted complexes
(s) and the supershifted complexes (ss) are indicated by the arrowsDNA–protein interactions by gel mobility shift assay. The anti-
bodies against panFos, Fra1, Fra2, cJun, JunB and JunD induced a
supershift of the labelled DNA probe incubated with nuclear
extracts from H460 (Figure 4), A549 and H520 (data not shown)
lung cells, indicating that their respective antigens participate in
the formation of the complex bound to this cis element. In H146
nuclear extracts (Figure 4; H82 and H187 data not shown),
however, only antibodies against cJun and JunD induced a super-
shift with this same labelled DNA probe. Antibodies to cFos and
FosB did not produce supershifts in H460 (Figure 4, left panel).
Supershifts using pan Fos, cFos, FosB, Fra1, Fra2, and JunB were
not observed using SCLC nuclear extracts (Figure 4). All gel shift
experiments were performed multiple times (at least five) and
produced similar results.
DISCUSSION
Although many studies of hNQO1 regulation have been reported,
these have been predominantly in liver systems (Jaiswal et al,
1988; Li and Jaiswal, 1992). The molecular mechanisms under-
lying increased NQO1 gene expression and activity in human
NSCLC are unknown. To examine NSCLC-specific expression of
NQO1, we transiently transfected a panel of deletion constructs
containing the hNQO1 promoter and the luciferase reporter gene
into both NSCLC and SCLC human cell lines. Deletion analysis of
the largest hNQO1 promoter region demonstrated that a 359 bp
proximal region (–608 to –259), which contains the ARE, was
critical in mediating basal expression in NSCLC. Deletion of the
sites for NFkB and AP-2 and the XRE did not significantly affect
hNQO1 promoter activity in either the NSCLC or SCLC cell lines.
Gel mobility shift experiments demonstrated the specific
binding of nuclear proteins to an oligomer containing the human
NQO1 ARE. Competition for binding to radiolabelled ARE was
observed with an oligomer containing an AP-1 site, but not with
oligomers containing the human NQO1 XRE, MPR or Oct-1
oligomers. Antibody supershift experiments using the broad-spec-
trum anti-Fos (antibody that reacts with all known Fos family
members) strongly suggest the participation of Fos family proteins
in the formation of the complexes that bind the ARE only in
nuclear extracts from NSCLC. A more detailed supershift analysis
using antibodies specific for each family member suggests that
Fra1, Fra2 and JunB are the AP-1 members found in NSCLC but
not in SCLC.
As early response genes, the Jun/Fos family is tightly regulated
during cellular differentiation (Karin et al, 1997) and rapidly
induced following growth factor stimulation (Coussens et al,
1994) or in proliferation processes (Angel and Karin, 1991). AP-1
activity has been associated with the regulation of many genes
(Busslinger and Bergers, 1994) including the positive regulation of
many phase II drug metabolizing genes in vitro (Diccianni et al,
1992; Friling et al, 1992; Prestera et al, 1993).
The patterns of expression of individual Fos family members
overlap but are not identical (Cohen and Curran, 1988; Angel and
Karin, 1991). Fra1 and Fra2 are both expressed at significant
levels in cycling cells, in contrast to cFos and FosB (Kovary and
Bravo, 1992). Fra1 has been identified in keratinocytes (Welter
et al, 1995) and cardiac tissue (Milivojevic and Gardner, 1995).
Fra1 is a unique member of the Fos gene family which is also
under positive control by AP-1 activity. It is capable of binding
different Jun proteins in a manner similar to that of other members
of the Fos family (Ryseck and Bravo, 1991). Unlike cFos, Fra1
lacks a transactivation domain (Suzuki et al, 1991; Wisdom and
Verma, 1993) yet possesses oncogenic potential (Bergers et al,
1995). Even though Fra1 lacks a transactivation domain, it could,
in theory, limit the Jun protein pool by competing for dimerization
partners. Fra1 has recently been shown to be a negative regulator
of antioxidant-mediated AP-1 activity in HeLa cells (Yoshioka
et al, 1995) and hNQO1 promoter activity in HepG2 human liver
cells (Venugopal and Jaiswal, 1996). However, the effects of Fra1
can also be dependent on cellular content. Expression studies with
the human atrial natriuretic factor (ANF) gene revealed divergent
regulation by Fra1 in rat cardiocytes (Milivojevic and Gardner,
1992). Interestingly, overexpressing Fra1 in atrial myocytes
mimicked the suppressant effects of cFos, while in the ventrical
myocyte, Fra1 behaved as a typical transcriptional activator of
ANF promoter activity (Milivojevic and Gardner, 1995). As to
JunB, the presence of JunB-binding activity in NSCLC cell lines is
in agreement with its possible role in NQO1 expression since JunB
is an efficient activator of promoters containing multimerized
AP-1 sites (Chiu et al, 1989). Only the ARE in the human NQO1
gene contains a centrally-located perfect AP-1 site flanked by two
imperfect AP-1 elements (Jaiswal et al, 1988). Additional studies
to confirm AP-1’s role in positive regulation of hNQO1 expression
in lung cancer cells, will require co-transfection experiments in
SCLC with vectors expressing the various absent AP-1 members.
Given the potential for temporal differences in the activation of the
individual AP-1 members and the stabilities of their protein pro-
ducts, such diversity of expression may represent novel mecha-
nisms controlling the transcription of hNQO1 during lung cancer
pathogenesis.
In summary, our results indicate that the ARE is critical to basal
NQO1 expression in lung tumours (NSCLC) expressing high
levels of DT-diaphorase. This initial investigation shows that Fra1,
Fra2 and JunB binding activities are not detected in SCLC and
thus suggests that SCLC lack the trans-activating factors of the
AP-1 family that mediate differential NQO1 expression in lung
tissue.
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